Bispecific Antibody‐Based Combination Therapies for B‐Cell Lymphomas: Current Evidence and Future Perspectives

Le résumé fourni par la source

The introduction of rituximab revolutionized the treatment landscape of B-cell lymphomas, establishing immunotherapy as a cornerstone of therapeutic strategies. Bispecific antibodies (BsAbs) have demonstrated remarkable efficacy in hematologic malignancies, including B-cell lymphomas, and select solid tumors. However, their single-agent activity remains limited by primary or acquired resistance. To overcome these challenges, current research has shifted toward exploring combination strategies integrating BsAbs with chemotherapy, targeted therapies, and other immunotherapies. This review comprehensively summarizes recent advances in BsAb-based combination therapies for B-cell lymphomas, with a focus on ongoing clinical trials and their preliminary outcomes. Furthermore, we discuss the mechanistic rationale, potential synergies, and challenges of these approaches, aiming to provide insights for optimizing future treatment paradigms.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.